Side-by-side · Research reference
ChonlutenvsHGH Fragment 176-191
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BAnimal-StrongHUMAN-REVIEWED28/59 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
01Mechanism of Action
Parameter
Chonluten
HGH Fragment 176-191
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Feedback intact?
—
N/A — does not interact with GH/IGF-1 axis
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Antibody development
—
Not reported in available studies
02Dosage Protocols
Parameter
Chonluten
HGH Fragment 176-191
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
Once daily (animal models)
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
—
Evidence basis
In vitro mechanistic
Animal studies only
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
—
Clinical validation
None (PubMed indexed)
—
Animal dose (IP)
—
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
Human equivalent dose
—
Not established — no published human RCTs
Detection window
—
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
Oral bioavailability
—
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
03Metabolic / Fat Loss Evidence
Parameter
Chonluten
HGH Fragment 176-191
Weight gain reduction
—
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
Body fat reduction
—
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
Lipolytic activity
—
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
Insulin sensitivity
—
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
IGF-1 impact
—
No elevation — fragment does not activate GH/IGF-1 axis
Beta-3 AR dependency
—
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
Human evidence
—
None published — pre-clinical only
04Side Effects & Safety
Parameter
Chonluten
HGH Fragment 176-191
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Human safety data
—
Not available — no published human trials
Metabolic profile
—
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
05Administration Protocol
Parameter
Chonluten
HGH Fragment 176-191
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Animal protocols: 14–19 days. Human duration not established — no published trials.
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015